Organogenesis Holdings (ORGO) Cash from Financing Activities (2016 - 2025)
Organogenesis Holdings has reported Cash from Financing Activities over the past 10 years, most recently at -$4.8 million for Q4 2025.
- Quarterly results put Cash from Financing Activities at -$4.8 million for Q4 2025, down 114.29% from a year ago — trailing twelve months through Dec 2025 was -$17.4 million (down 162.81% YoY), and the annual figure for FY2025 was -$17.4 million, down 162.81%.
- Cash from Financing Activities for Q4 2025 was -$4.8 million at Organogenesis Holdings, up from -$10.2 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for ORGO hit a ceiling of $33.6 million in Q4 2024 and a floor of -$10.2 million in Q3 2025.
- Median Cash from Financing Activities over the past 5 years was -$1.1 million (2023), compared with a mean of $76850.0.
- Biggest five-year swings in Cash from Financing Activities: crashed 5630.77% in 2023 and later soared 1993.58% in 2024.
- Organogenesis Holdings' Cash from Financing Activities stood at -$917000.0 in 2021, then plummeted by 104.47% to -$1.9 million in 2022, then increased by 5.23% to -$1.8 million in 2023, then soared by 1993.58% to $33.6 million in 2024, then crashed by 114.29% to -$4.8 million in 2025.
- The last three reported values for Cash from Financing Activities were -$4.8 million (Q4 2025), -$10.2 million (Q3 2025), and -$288000.0 (Q2 2025) per Business Quant data.